Koss Olinger Consulting LLC Buys Shares of 10,362 MiMedx Group, Inc. (NASDAQ:MDXG)

Koss Olinger Consulting LLC purchased a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 10,362 shares of the company’s stock, valued at approximately $100,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MDXG. JPMorgan Chase & Co. boosted its holdings in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after buying an additional 215,995 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after buying an additional 174,797 shares in the last quarter. Barclays PLC boosted its holdings in shares of MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after buying an additional 163,005 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of MiMedx Group by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after buying an additional 92,726 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of MiMedx Group during the 4th quarter worth approximately $887,000. 79.15% of the stock is currently owned by institutional investors.

Insider Activity at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now directly owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $430,762.44. Following the sale, the chief accounting officer now directly owns 440,178 shares of the company’s stock, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 142,259 shares of company stock valued at $1,116,170. 1.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Price Performance

Shares of MDXG opened at $8.09 on Thursday. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The business’s fifty day moving average is $8.40 and its 200 day moving average is $7.84. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The stock has a market cap of $1.19 billion, a P/E ratio of 14.71 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. Sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.